1. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.

    Molecular Cancer Therapeutics 15(8):1809 (2016) PMID 27235164 PMCID PMC4975626

    Recent findings suggest that the inhibition of Aurora A (AURKA) kinase may offer a novel treatment strategy against metastatic cancers. In the current study, we determined the effects of AURKA inhibition by the small molecule inhibitor MLN8237 both as a monotherapy and in combination with the mi...
  2. A proposed staging system and stage-specific interventions for familial adenomatous polyposis.

    Gastrointestinal Endoscopy 84(1):115 (2016) PMID 26769407

    It is not possible to accurately count adenomas in many patients with familial adenomatous polyposis (FAP). Nevertheless, polyp counts are critical in evaluating each patient's response to interventions. However, the U.S. Food and Drug Administration no longer recognizes the decrease in polyp bu...
  3. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy.

    The Canadian journal of urology 23(3):8271 (2016) PMID 27347619

    To describe immediate perioperative outcomes of robot-assisted laparoscopic salvage radical prostatectomy for recurrent cancer following radiation therapy, and compare outcomes to a contemporary open surgical cohort. A total of 39 patients underwent salvage radical prostatectomy with pelvic lymp...
  4. Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients.

    Antimicrobial Agents and Chemotherapy 60(3):1830 (2016) PMID 26824940 PMCID PMC4775958

    The current recommendations for intravenous (i.v.) acyclovir dosing in obese patients suggest using ideal body weight (IBW) rather than total body weight (TBW). To our knowledge, no pharmacokinetic analysis has validated this recommendation. This single-dose pharmacokinetic study was conducted i...
  5. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.

    Cytotherapy 17(12):1785 (2015) PMID 26475754 PMCID PMC4700501

    Hematopoietic cell mobilization with granulocyte-colony stimulating factor (G-CSF) and plerixafor results in superior CD34+ cell yield compared with G-CSF alone in patients with myeloma and lymphoma. However, plerixafor-based approaches may be associated with high costs. Several institutions use...
  6. Palliative Care Training during Fellowship: A National Survey of U.S. Hematology and Oncology Fellows.

    Journal of Palliative Medicine 18(9):747 (2015) PMID 26098204 PMCID PMC4696424

    Despite requirements for palliative care training during fellowship, there is a paucity of recent data regarding the attitudes, knowledge, and skills of hematology/ oncology fellows in palliative care. Our aim was to assess fellows' attitudes toward and quality of training in palliative care dur...
  7. A comparison of tissue engineering based repair of calvarial defects using adipose stem cells from normal and osteoporotic rats.

    Bone 78:1 (2015) PMID 25940459 PMCID PMC4466199

    Repairing large bone defects presents a significant challenge, especially in those people who have a limited regenerative capacity such as in osteoporotic (OP) patients. The aim of this study was to compare adipose stem cells (ASCs) from both normal (NORM) and ovariectomized (OVX) rats in osteog...
  8. Response to Comment on "Appalachian Mountaintop Mining Particulate Matter Induces Neoplastic Transformation of Human Bronchial Epithelial Cells and Promotes Tumor Formation".

    Environmental Science & Technology 49(15):9385 (2015) PMID 26207860

  9. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

    Antimicrobial Agents and Chemotherapy 59(8):4424 (2015) PMID 25987632 PMCID PMC4505228

    Posaconazole (PCZ), approved for prophylaxis against invasive fungal disease in high-risk patients, is commercially available orally as a suspension formulation (PCZ-susp) and as a delayed-release tablet (PCZ-tab). We evaluated the serum steady-state concentrations (Css) of PCZ stratified by the...
  10. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

    Cancer 121(14):2411 (2015) PMID 25832466 PMCID PMC4490036

    Receptors in tumor blood vessels are attractive targets for ligand-directed drug discovery and development. The authors have worked systematically to map human endothelial receptors ("vascular zip codes") within tumors through direct peptide library selection in cancer patients. Previously, they...
  11. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

    PNAS 112(27):8403 (2015) PMID 26080435 PMCID PMC4500257

    Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker but its function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant, which harbors the PCA3 locus, thereby classifying PCA3 as an antisense intronic long noncoding (lnc)RNA. We show that P...
  12. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.

    Supportive Care Cancer 23(3):661 (2015) PMID 25160493

    Calcium aluminosilicate clay (CASAD) is a naturally occurring clay that serves as a cation exchange absorbent. We hypothesized that oral administration of CASAD would reduce the rate of grade 3/4 diarrhea associated with irinotecan use for metastatic colorectal cancer (CRC) by adsorbing the SN-3...
  13. Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients.

    The Journal of community and supportive oncology 13(3):113 (2015) PMID 26287033 PMCID PMC4792513

    Patients receiving chemotherapy are at risk for febrile neutropenia following treatment. The American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) recommend screening patients for risk of febrile neutropenia and risk stratification based on likelihood of f...
  14. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

    European Urology 67(1):53 (2015) PMID 24882673 PMCID PMC4247811

    Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). To evaluate enzalutamide's effects on cancer and on androgens in blood and bone marrow, and associate these with clinical observations. In this prospective phase 2 study, 60 pati...
  15. Radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer.

    The Journal of community and supportive oncology 13(1):27 (2015) PMID 25839063

    Radiation exposure is associated with an increased risk of secondary cancers. Knowing the approximate radiation exposure from diagnostic procedures in the œrst year after a breast cancer diagnosis could help educate patients and allow physicians to monitor them more closely for potential risks. ...
  16. Appalachian mountaintop mining particulate matter induces neoplastic transformation of human bronchial epithelial cells and promotes tumor formation.

    Environmental Science & Technology 48(21):12912 (2014) PMID 25347054 PMCID PMC4224494

    Epidemiological studies suggest that living near mountaintop coal mining (MTM) activities is one of the contributing factors for high lung cancer incidence. The purpose of this study was to investigate the long-term carcinogenic potential of MTM particulate matter (PMMTM) exposure on human bronc...
  17. Diabetes, diabetes treatment and breast cancer prognosis.

    Breast Cancer Research and Treatment 148(1):153 (2014) PMID 25261292 PMCID PMC4393950

    The objectives of this study are to assess the impact of pre-existing diabetes and diabetes treatment on breast cancer prognosis. 8,108 women with centrally confirmed invasive breast cancer in the Women's Health Initiative diagnosed between 1998 and 2013 were followed through the date of death o...
  18. Weight change associated with third-generation adjuvant chemotherapy in breast cancer patients.

    The Journal of community and supportive oncology 12(10):355 (2014) PMID 25853257

    Studies have shown that breast cancer treatment can cause an increase in weight. Weight gain during chemotherapy is usually significant and may be associated with poor survival. However, the role of third- generation chemotherapy regimens and weight gain is not well reviewed. We retrospectively ...
  19. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

    Clinical Cancer Research 20(18):4827 (2014) PMID 24987059 PMCID PMC4518867

    The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer. Outcomes of patients who were referred for treatment on phase I cl...
  20. Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.

    Biology of Blood and Marrow Transplantation 20(3):415 (2014) PMID 24361913 PMCID PMC4557764

    Thirty-day readmission (30-DR) has become an important quality-of-care measure. Allogeneic hematopoietic cell transplantation (allo-HCT) presents a medical setting with higher readmission rates. We analyzed factors affecting 30-DR and its impact on patient outcomes and on health care costs in 91...